ATOS
Closed
Atossa Genetics Inc
0.8242
-0.0058 (-0.70%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 0.83
Day's Range: 0.8201 - 0.84645
Send
sign up or login to leave a comment!
When Written:
0.7249
Atossa Genetics Inc. is a clinical-stage pharmaceutical company that focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded in 2009 and is headquartered in Seattle, Washington.
Atossa Genetics is primarily focused on developing its proprietary Endoxifen program, which is designed to treat breast cancer and prevent breast cancer recurrence. Endoxifen is a metabolite of tamoxifen, a commonly used breast cancer drug, and has been shown to be more effective than tamoxifen in preclinical studies.
In addition to its Endoxifen program, Atossa Genetics is also developing a topical drug delivery system called the Microcatheter Breast Delivery System. This system is designed to deliver drugs directly to the breast tissue, which could potentially improve the effectiveness of breast cancer treatment while reducing side effects.
Atossa Genetics is a publicly traded company and is listed on the NASDAQ stock exchange under the ticker symbol ATOS.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Atossa Genetics is primarily focused on developing its proprietary Endoxifen program, which is designed to treat breast cancer and prevent breast cancer recurrence. Endoxifen is a metabolite of tamoxifen, a commonly used breast cancer drug, and has been shown to be more effective than tamoxifen in preclinical studies.
In addition to its Endoxifen program, Atossa Genetics is also developing a topical drug delivery system called the Microcatheter Breast Delivery System. This system is designed to deliver drugs directly to the breast tissue, which could potentially improve the effectiveness of breast cancer treatment while reducing side effects.
Atossa Genetics is a publicly traded company and is listed on the NASDAQ stock exchange under the ticker symbol ATOS.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!